Company intelligence / Profile preview

Piomic Medical

Zürich, Zurich, Switzerlandpiomic.com ↗

Ownership: Private
Development stage: Commercial

Overview

Piomic’s COMS® One Therapy System has CE mark approval and has demonstrated efficacy in accelerating wound healing—clinical trials showed a 2.5x faster healing rate for chronic wounds compared to standard care. Over 10,000 treatments have been performed across more than 30 Swiss hospitals with positive feedback from clinicians and patients. The company’s pivotal MAVERICKS trial in the US targets refractory diabetic foot ulcers.

Therapeutic areas: DermatologyEndocrinology
Modalities: DeviceOptical StimulationMagnetic Stimulation
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

COMS One

Commercial

Indications: Hard-to-heal wounds, Diabetic foot ulcer

1 more asset in the full pipeline.

Request access →

Partnerships

Eurostars funding for R&D collaboration on next-gen product

Beyond the preview

Go deeper on Piomic Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Piomic Medical.

Explore the full profile